Menopause test kit

for breast cancerhormonalCA 15-3

Female breast cancer has now surpassed lung cancer as the leading cause of global cancer incidence in 2020. The elevated incidence rates in higher HDI countries reflect a longstanding higher prevalence of reproductive and hormonal risk factors (early age at menarche, later age at menopause, advanced age at first birth, fewer number of children, less breastfeeding, menopausal hormone therapy, oral contraceptives) and lifestyle risk factors (alcohol intake, excess body weight, physical inactivity), as well as increased detection through organized or opportunistic mammographic screening. Some serum tumor markers including CA15-3 and CEA have been reported to be elevated in some patients with breast cancer. Clinical Significance CA15-3 is recommended to be used in postoperative surveillance in patients with no evidence of disease, monitoring therapy in advanced disease, assessing prognosis. High preoperative levels (e.g. >30 U/L) always predict adverse outcome.[2] CEA can be used in post-operative surveillance in patients with no evidence of disease, monitoring therapy in advanced disease, especially if CA 15-3/BR 27.29 is not elevated. And it can also be used in assessing prognosis that high preoperative levels predict adverse outcome.[2]